Could DehydraTECH(TM) CBD be Worth $3 Billion a Year to Lexaria?


New York, New York–(Newsfile Corp. – March 9, 2021) – PCG Digital — Hypertension, or high blood pressure as it’s commonly known, affects over three million Americans every year and is a primary or contributing cause of death for 25% of them. On a global scale, hypertension kills roughly 7.6 million people per year.

Lexaria Bioscience, a Canadian biotech firm specializing in cannabinoid research, is hoping to change those numbers. DehydraTECH CBD, the company’s revolutionary oral deliverable for hypertension sufferers, is in human clinical trials right now and results are promising.

“Our 2018 human clinical trial showed that DehydraTECH CBD lowers blood pressure by about 5% after just a single 90 milligram dose,” said Lexaria CEO Chris Bunka. “Generic CBD doesn’t do that. Our objective in our new 2021 clinical studies is to evidence a 10% or greater drop in blood pressure to be competitive with industry demands.”

The 2018 European study also showed evidence of DehydraTECH CBD facilitating higher volumes of blood flow to the brain and faster delivery of CBD into the bloodstream. Ensuing studies will determine what that means for hypertension sufferers.

New Human Clinical Studies are Underway in 2021

Lexaria currently has three human clinical studies about to commence, using 300 to 450 milligram doses. In comparison, GW Pharmaceuticals is administering up to 1200 milligrams of Epidiolex, an FDA-approved CBD-based anti-seizure medicine for children, and even at those higher doses side effects have been minimal.

“In the hypertension industry, drugs that provide a 10 to 20 percent reduction in blood pressure are generally successful,” Bunka adds. “We are confident we can get to that level and expect our studies to provide evidence supporting that over the next six to nine months.”

DehydraTECH CBD utilizes a patented dehydration process that changes how the body senses and absorbs drugs orally. In earlier clinical trials, DehydraTECH CBD has been proven to deliver over 300% more CBD than generic CBD in less than 30 minutes.

Positive results in the human clinical studies would provide more evidence for consideration of DehydraTECH CBD as a regulated form of CBD, a status in the cannabinoid sector that only Epidiolex has earned to date. Bunka and his team are confident they will get there.

Hypertension Relief is a $30 Billion Market

There are obvious health care benefits to developing an effective cannabis-based hypertension treatment. Financially, a success in this area would be huge for Lexaria. In 2019, the market for antihypertensive drugs was worth $26.1 billion.

By comparison, the pediatric anti-seizure market that Epidiolex serves is worth ~$1 billion per year. GW Pharmaceuticals was just purchased for $7.2 billion by Jazz Pharmaceuticals, a major Big Pharma player. In the United States alone, there are three antihypertension drugs that have recorded between $1 and $3 billion in annual sales:

None of these drugs are cannabis-based and each has unwanted side effects. Assuming Lexaria reaches that level, the company could be looking at a drug with over $1 billion in annual revenue after FDA approval. What might Lexaria be worth at that point?

With existing patents granted in the EU and Australia already secured for the treatment of heart disease using cannabinoids, Lexaria is confident it will receive regulator approvals in multiple geographic markets in due time. Investors seem to agree. As of this morning, Lexaria (LEXX) was up over 25% since first listing on Nasdaq in January.

Lexaria is Open to Partnership Opportunities

CEO Bunka sees the opportunity and is open to partnering with a larger company. “Lexaria would be open to partner with Big Pharma to deliver this potentially life-saving treatment,” he said. “Our business model includes out-licensing our technology for appropriate royalty streams.”

Companies with a royalty revenue stream have been known to earn a valuation of up to 30 times annual revenue. If you do the math on the partnership possibilities, Lexaria could be looking at valuations as high as GW Pharmaceuticals recently reached. That’s not unrealistic in this sector.

With Lexaria, it’s possible to happen soon as they are not reliant on government funding to conduct clinical studies: All existing trials are 100% funded from internal company resources. Therefore, the ramp-up to commercialization can be faster, and these potential revenues, can have a significant impact on its current market cap of only $35 million.

“The Jazz acquisition of GW shows that Big Pharma is finally taking cannabinoid research and CBD-based medical treatments seriously,” Chris Bunka said. “One of the big benefits of CBD is its modest side effect profile – pharma simply HAS to research this thoroughly in the interests of public health.”

This story will be worth keeping an eye on as it unfolds. Results from Q1 studies of DehydraTECH CBD will be made available starting around May, with human clinical study results to follow soon thereafter. If all goes well, the path to FDA approval could become clearer. Relief for hypertension sufferers can’t come soon enough.


This communication was produced by PCG Digital Holdings, LLC, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this may be ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). PCG may be compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy.

PCG is not a registered or licensed broker, dealer, broker-dealer, investment adviser nor investment manager, nor does PCG engage in any activities that would require such registrations. PCG does not provide investment advice, endorsement, analysis or recommendations with respect to any securities, and its services to or statements about its clients should never be construed as any endorsement of or opinion about any security of any client. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other similar product or service regardless of whether such security, product, or service is referenced in this communication. Further, nothing in this communication is intended to provide tax, legal, or investment advice and nothing in this communication should be construed as a recommendation to buy, sell or hold any investment or security or to engage in any investment strategy or transaction. For full disclaimers, including compensation received for professional services, please visit


To view the source version of this press release, please visit